Camena has appointed Dr Nicola Thompson as Chair of its Board

Camena Bioscience – a synthetic biology company providing genes to the pharmaceutical and biotechnology industries – has appointed Dr Nicola Thompson as Chair of its Board of Directors.

Following its $10 million Series A financing earlier in the year, the appointment forms part of the company’s growth plans to expand commercialisation of its pioneering DNA synthesis platform, gSynth.

Nicola is an industry leader, with experience developing and commercialising innovative technologies and therapeutic modalities.

She was the founding CEO of Amphista Therapeutics, successfully steering the company through a $7.5 million Series A, a $53 million Series B and established partnerships with leading pharmaceutical companies with a combined deal value of more than $2 billion.

Prior to Amphista, she was Chair of the Board at Nanna Therapeutics, playing a key role in corporate development and its successful acquisition by Astellas. Nicola also held senior leadership roles at Roche, where she built and led pRED’s external drug discovery organisation, and in business development at GSK.

Dr Nicola Thompson, Chair of the Board, Camena Bioscience, added: “I am delighted to join the Company as its Chair at this pivotal stage of growth. The leadership team are recognised pioneers in the field and the existing Board has an impressive array of investment and entrepreneurial experience, which will collectively support Camena on their scale-up journey.”